B+
Bull case
25%
Probability
Target price
$1.55
Analysis reference price unavailable
Analysis 2026-08-20 · RankAlpha Sentiment Codex
CYPH
CypherpunkFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$1.18
Analysis reference price unavailable
Analysis 2026-08-20 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-08-20 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-20
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+3.0
Score
AI commentary
The post-earnings evidence is mixed but eventful: the company disclosed treasury growth, FDA alignment, and a major mining-asset transaction, offset by the clinical endpoint miss and potential dilution. The August 19 anchor price of $1.07 does not establish a trustworthy market-reaction attribution, and analyst revisions remain unavailable. Low coverage and loose peers warrant monitoring-style conviction rather than a strong directional thesis.
RankAlpha Sentiment Codex - 2026-08-20
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-17eventMining-fleet acquisition creates a near-term execution and dilution testHigh impact
The August 17 asset purchase agreement acquired mining equipment and hosting agreements for $33.3 million through a pre-funded warrant for 43.29 million shares, subject to exercise limits and future stockholder approval requirements [#8-K-2026-08-18]. Successful deployment could support Zcash treasury growth, while dilution and execution concerns could pressure the stock.
2026-08-20eventQ2 update reinforced treasury growth and FDA-aligned Phase 3 pathHigh impact
The Q2 filing reported 323,394.38 ZEC held as of August 11 and FDA alignment on a proposed biomarker-selected Phase 3 sirexatamab trial. However, the DeFianCe prespecified primary endpoint was not met in the intent-to-treat population, making the read-through mixed rather than a clean earnings beat [#SEC-8K-2026-08-12].
2027-06-30catalystBiomarker-selected Phase 3 financing or partnership milestoneHigh impact
Leap is pursuing a strategic path for sirexatamab as either an independently financed spin-out or through a partner, following FDA feedback on a randomized Phase 3 design. The milestone is potentially material but remains dependent on funding, enrollment, and execution [#SEC-8K-2026-08-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-20 • Updated nightlySource: Internal modelMethodology